Key facts
- This page summarizes Mangini Siobhan Nolan's Form 4 filing for NGM BIOPHARMACEUTICALS INC.
- 3 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 06 Mar 2023, 16:12.
Mangini Siobhan Nolan - 02 Mar 2023 Form 4 Insider Report for NGM BIOPHARMACEUTICALS INC
- Reporting relationship
- President and CFO
- Issuer ticker
- N/A
- Reported as of
- 02 Mar 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 06 Mar 2023, 16:12:06 UTC
- Prior SEC filing
- 01 Jul 2022
- Next SEC filing
- 03 Jan 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Valerie Pierce, Attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Mangini Siobhan Nolan filed Form 4 for NGM BIOPHARMACEUTICALS INC on 06 Mar 2023.
Change
- Previous filing in this sequence was filed on 01 Jul 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
NGM
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +76,000
- Change %
- Price
- $0.000000
- Shares after
- 76,000
- Date
- 02 Mar 2023
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
NGM
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +228,000
- Change %
- Price
- $0.000000
- Shares after
- 228,000
- Date
- 02 Mar 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 228,000
- Exercise price
- $4.36
- Footnotes
- F2
NGM
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +200,000
- Change %
- Price
- $0.000000
- Shares after
- 200,000
- Date
- 02 Mar 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 200,000
- Exercise price
- $4.36
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Represents shares of common stock issuable upon the vesting and settlement of restricted stock units ("RSUs"). 1/4th of the RSUs vest on each of January 15, 2024, January 15, 2025, January 15, 2026 and January 15, 2027.
Footnote F2
The shares subject to the stock option vest over a four-year period commencing January 1, 2023, with 1/48th of the shares vesting on a monthly basis.
Footnote F3
1/2 of the shares subject to the stock option vest on the first anniversary of the grant date of March 2, 2023 (the "2023 Grant Date"), and the remaining 1/2 of the shares vest on the second anniversary of the 2023 Grant Date.